CN101513451B - Lotus Leaf extract, preparation method and application thereof - Google Patents
Lotus Leaf extract, preparation method and application thereof Download PDFInfo
- Publication number
- CN101513451B CN101513451B CN2009100643537A CN200910064353A CN101513451B CN 101513451 B CN101513451 B CN 101513451B CN 2009100643537 A CN2009100643537 A CN 2009100643537A CN 200910064353 A CN200910064353 A CN 200910064353A CN 101513451 B CN101513451 B CN 101513451B
- Authority
- CN
- China
- Prior art keywords
- extract
- folium nelumbinis
- ethyl acetate
- acetone
- lotus leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a lotus leaf extract, a preparation method and the application thereof; wherein, the extract takes the lotus leaf as raw material, the lotus leaf is quenched, filtered and decompressed by the blended solution of the acetone and water to recycle the acetone and obtain lotus leaf aqueous solution, and then the lotus leaf aqueous solution is respectively leached by ethyl acetate and normal butanol to obtain ethyl acetate extract and normal butanol extract. The ethyl acetate extract and normal butanol extract of the lotus leaf respectively lavage a mouse; carbon tetrachloride induces the liver damage of the laboratory mouse; ALT and AST value in the blood serum of the mouse and the SOD and MDA value in the hepatic tissue are detected; experiments show that the ethyl acetate extract and normal butanol extract of the lotus leaf can effectively reduce the ALT, AST and MDA value of the carbon tetrachloride hepatic tissue mouse and can obviously increase the SOD vitality of the hepatic cell of the mouse. The results show that the ethyl acetate extract and normal butanol extract of the lotus leaf have the function of reducing serum transaminase and lipid peroxidation, thereby illustrating that the ethyl acetate extract and normal butanol extract of the lotus leaf have the function of protecting the liver.
Description
Technical field
The present invention relates to a kind of Folium Nelumbinis extract, simultaneously, also related to a kind of preparation method and application of this Folium Nelumbinis extract.
Background technology
Hepatopathy and hepatic injury are that a kind of number of the infected is many, to the bigger disease kind of human body harm, a lot of harmful factors can cause hepatic injury, mainly contain types such as viral hepatitis, alcoholic hepatitis, drug induced hepatitis and fatty liver, its clinical manifestation is serum transaminase rising, lobules of liver necrosis, fatty liver, cholestasis, hepatic fibrosis, even can be converted into liver cirrhosis and hepatocarcinoma.Liver is human maximum metabolism organ, and all metabolism in liver of various medicines and poisonous substance are so hepatic disease is one of the most common disease that influences human health.Research to hepatology is focus in recent decades always in the world, but is still global severe problem for the effective prevention and the treatment of hepatic injury.At present, be used for the treatment of hepatic injury and adopt Western medicine mostly, Western medicine expense height is treated longly with the phase, and has toxic and side effects, is difficult for being accepted by extensive patients.
Folium Nelumbinis is the dried leaves of Nymphaeceae (Nelumbo nucifera Garrtn) plant lotus, and all there is distribution countries in the world, in the most of area of China distribution is arranged all also, main product in the Hunan, ground such as Hubei, Zhejiang, Jiangsu.The Folium Nelumbinis hardship, flat, return liver, spleen, stomach warp, have effects such as expelling summer-heat heat clearing away, the clear sun of hair growth promoting, dissipating blood stasis hemostasis.In November, 1991, the prison of defending of Ministry of Public Health is sent out in (1991) No. 45 files, and Folium Nelumbinis is put among the list of the 2nd batch " be food be again medicine ".Chemical constitution study to Folium Nelumbinis shows that the chemical constituent of Folium Nelumbinis mainly contains alkaloids, flavonoid, volatile oil and organic acid.Modern pharmacology to Folium Nelumbinis studies show that, Folium Nelumbinis has antioxidation in vitro, antibiotic, antiviral and inhibition action of lipase, and activity in vivo mainly contains blood fat reducing and effect of weight reducing.
The Folium Nelumbinis pharmacologically active is mainly more to study its water-alcohol extraction, does not see that its ethyl acetate and n-butanol extract are to the acute liver damage protection of tetrachloro-methane induction and the relevant report of therapeutical effect.
Summary of the invention
The object of the present invention is to provide a kind of Folium Nelumbinis extract.
The present invention also aims to provide a kind of preparation method of Folium Nelumbinis extract.
In addition, the object of the invention also is to provide the application of a kind of Folium Nelumbinis extract aspect preparation treatment hepatic disease medicine.
To achieve these goals, technical scheme of the present invention has adopted a kind of Folium Nelumbinis extract, with the Folium Nelumbinis is raw material, with mixed solution merceration, the filtration of Folium Nelumbinis through acetone and water, reclaim under reduced pressure acetone, the Folium Nelumbinis aqueous solution, after get ethyl acetate extract and n-butanol extract through ethyl acetate and n-butanol extraction respectively.
Extracting method is specific as follows: gets the Folium Nelumbinis dry product,, in the mixed solution of acetone and water, repeats merceration 2-4 time through pulverizing, and sucking filtration, merging filtrate and reclaim under reduced pressure acetone get the Folium Nelumbinis aqueous solution, use earlier ethyl acetate extraction for the first time, get ethyl acetate extract; To extract the back surplus solution and obtain n-butanol extract with n-butanol extraction.
The volume ratio of acetone and water is in the mixed solution of described acetone and water: acetone=(6-8)/(2-4).
Described merceration divides 3 times, and 6-8 days for the first time, back twice 2-4 days.
Technical program of the present invention also lies in adopting a kind of preparation method of Folium Nelumbinis extract, may further comprise the steps: get the Folium Nelumbinis dry product, through pulverizing, in the mixed solution of acetone and water, repeat merceration 2-4 time, sucking filtration, merging filtrate and reclaim under reduced pressure acetone get the Folium Nelumbinis aqueous solution, use earlier ethyl acetate extraction for the first time, get ethyl acetate extract; To extract the back surplus solution and obtain n-butanol extract with n-butanol extraction.
The volume ratio of acetone and water is in the mixed solution of described acetone and water: acetone=(6-8)/(2-4).
Described merceration divides 3 times, and 6-8 days for the first time, back twice 2-4 days.
Further, technical scheme of the present invention has adopted a kind of Folium Nelumbinis extract to be used to prepare the application of treatment hepatic disease medicine aspect.
Further, technical scheme of the present invention has adopted a kind of Folium Nelumbinis extract to be used to prepare the application of hepatic aspect.
Folium Nelumbinis ethyl acetate extract of the present invention and n-butanol extract are irritated the stomach mice respectively, with the hepatic injury of tetrachloro-methane induction experiment mice, detect ALT and AST value in the mice serum, and SOD in the hepatic tissue and MDA value, experiment shows: Folium Nelumbinis ethyl acetate extract and n-butanol extract all can effectively reduce the ALT value of carbon tetrachloride hepatic injury mice, AST value and MDA value, and the SOD energy value of the mouse liver cell that can raise significantly.
The result shows that Folium Nelumbinis ethyl acetate extract and n-butanol extract all have the effect of transaminase lowering and lipid peroxidation, illustrates that Folium Nelumbinis ethyl acetate extract and n-butanol extract all have hepatoprotective effect.
Folium Nelumbinis ethyl acetate extract of the present invention and n-butanol extract, can make various preparations based on peroral dosage form, comprise: tablet, pill, granule, microcapsule, syrup, oral liquid, injection and slow releasing agent and other acceptable dosage form, Folium Nelumbinis extract provided by the present invention is evident in efficacy for treatment hepatic disease, improvement and recovery liver function aspect, and can be used as the health product use.
The specific embodiment
Embodiment 1
Present embodiment is a Folium Nelumbinis extract---the preparation method concrete steps of ethyl acetate extract and n-butanol extract are as follows: get the Folium Nelumbinis dry product, pulverize, with the mixed solution merceration of acetone and water 3 times, wherein the volume ratio of acetone and water is in the mixed solution of acetone and water: acetone=7/3,7 days for the first time, the back is 3 days twice, sucking filtration, merging filtrate and reclaim under reduced pressure acetone obtain the Folium Nelumbinis aqueous solution, use earlier ethyl acetate extraction for the first time, get ethyl acetate extract; To extract the back surplus solution and obtain n-butanol extract with n-butanol extraction.
Embodiment 2
Present embodiment is the hepatoprotective effect experiment of Folium Nelumbinis ethyl acetate extract and n-butanol extract.
Method: intracorporal method-tetrachloro-methane induction chmice acute liver injury model
Principle: CCl
4Be to use the earliest, hepatic injury the most widely, hepatic fibrosis derivant, in inducing the acute liver damage experiment, be the most frequently used medicine.CCl
4Liver toxicity mechanism consistent being known as: CCl
4Reductive metabolism becomes CCl under the effect of P-450 enzyme
3, CCl
3Generate fatty acid profile with the reaction of unsaturated acids on the cell membrane, thereby cause that lipid peroxidation causes cell membrane, organelle damage, and can activate mechanism such as tumor necrosis factor.For CCl
4In the research of inducing mouse liver injury model, it is some at first to choose healthy KM male mice, and random packet is irritated the corresponding medicine of stomach respectively once a day according to group, after 8 days, makees solvent with commercially available refined soybean oil and prepares 0.4%CCl
4Oil solution, according to mice body weight 10ml/kg lumbar injection, fasting can't help detecting behind the water 16h superoxide dismutase SOD in glutamate pyruvate transaminase (ALT), glutamic oxaloacetic transaminase, GOT (AST) and the hepatic tissue in the mice serum), malonaldehyde (MDA).ALT and AST mainly are distributed in the hepatocyte of liver, if hepatic necrosis, a large amount of ALT and AST will discharge in the blood.But these two kinds of enzyme distributions in hepatocyte are different.ALT is distributed in liver cytoplasm, and AST is distributed in liver cytoplasm and the mitochondrion.The chronic hepatitis of acute hepatitis and light disease mainly shows as the rising of ALT.The later stage of chronic hepatitis, liver cirrhosis and liver cancer patient, hepatocellular destructiveness is serious, mitochondrion also has been subjected to serious destruction, so AST raises obviously.Because ALT and the responsive reflection hepar damnification degree of AST energy are so ALT and AST are the important indicators of investigating liver function.
Instrument: UV-2000 type ultraviolet-uisible spectrophotometer (but You Ni Shanghai Instr Ltd.), CS-H1 type blender (Beijing is won and encouraged positive scientific ﹠ technical corporation), the biochemical incubator (Shanghai one permanent Science and Technology Ltd.) of LRH-150, Multiskan MK3 microplate reader (thermoelectric Shanghai Instr Ltd.), TGL-16 high speed centrifuge (big instrument plant in Jintan City, Jiangsu), the tissue refiner of 985370-395 type (BIOSREC, Mexico), all size pipettor etc.
Reagent: ALT, AST, SOD, MDA detection kit (be Nanjing and build up bio-engineering research institute); DANGFEI LIGANNING JIAONANG (Meidakang Pharmaceutical Co., Ltd., Sichuan Prov.; product batch number: 080302); Coomassie brilliant blue G250 (packing factory of Shanghai chemical reagents corporation; lot number: 20050115), other reagent are analytical pure.
Method: get healthy KM mice, all male, body weight 18～22g is divided into 9 groups at random, 10 every group, is respectively high, normal, basic group of blank group, model group, DANGFEI LIGANNING JIAONANG group, high, normal, basic group of Folium Nelumbinis ethyl acetate and Folium Nelumbinis n-butyl alcohol.Blank group, model group are irritated the CMC-Na solution 20mL/kg of stomach 0.4% every day; The DANGFEI LIGANNING JIAONANG group is irritated stomach 1.4g/kg every day, the high, medium and low dosage group of Folium Nelumbinis ethyl acetate extract is irritated stomach 0.523g/kg, 0.2615g/kg and 0.1308g/kg respectively, and the high, medium and low dosage group of Folium Nelumbinis n-butanol extract is irritated stomach 0.8405g/kg, 0.4205g/kg and 0.21g/kg respectively.After 8 days, behind the administration 2h, except that the blank group, each group is according to the CCl of mice body weight 10ml/kg lumbar injection 0.4%
4Peanut oil solution, after water 16h is can't help in fasting, plucking eyeball gets blood and isolates serum, detect ALT and AST, isolating liver weighs, and the liver of the about 300mg of weighing and about 30mg measures MDA and SOD with the liver homogenate liquid of 0～3 ℃ of normal saline homogenate (surveying MDA) and 1% (surveying SOD) that become 10%, and Coomassie brilliant blue is except that albumen.
The mensuration of ALT, AST, SOD and MDA is all carried out according to the requirement of test kit, and experimental data represents that with mean ± standard deviation the experimental result statistics adopts spss10.0 software to carry out one factor analysis of variance.
The result:
(1) Folium Nelumbinis ethyl acetate extract and n-butanol extract all have effect of reducing enzyme levels
As known from Table 1, senior middle school's dosage of Folium Nelumbinis two extract parts and model group significantly reduce transaminase ALT and AST in the mice body.Both reduce ALT and AST all has dose dependent.
(2) Folium Nelumbinis ethyl acetate extract and n-butanol extract lipoid peroxidization resistant
By table 2 data as can be known, Folium Nelumbinis two extraction unit potential energies significantly reduce MDA content in the liver organization, Folium Nelumbinis n-butanol portion particularly, and energy increased SOD, prompting Folium Nelumbinis two extract parts improve one of mechanism of hepatic injury and are lipoid peroxidization resistant, and are to come lipoid peroxidization resistant by SOD activity improving.
Each medicine of table 1 is to Serum ALT of tetrachloro-methane induction hepatic injury mice and the influence of AST
Compare with the blank group:
#P＜0.05;
##P＜0.01;
###P＜0.001
Compare with model group:
*P＜0.05;
*P＜0.01;
* *P＜0.001
Each medicine of table 2 is to hepatic tissue MDA of tetrachloro-methane induction hepatic injury mice and the influence of SOD
Compare with the blank group:
#P＜0.05;
##P＜0.01;
###P＜0.001
Compare with model group:
*P＜0.05;
*P＜0.01;
* *P＜0.001
Experimental result shows: senior middle school's dosage of ethyl acetate extract and n-butanol extract significantly reduces ALT and AST, and and reduce MDA in the hepatic tissue, the anti peroxidation of lipid thing mechanism of increased SOD is relevant.
Following examples mainly are liver disease medicine and the health product based on the preparation peroral dosage form.
Embodiment 3
Present embodiment is: get Folium Nelumbinis n-butanol extract extractum 1082.32g or Folium Nelumbinis ethyl acetate extract extractum 695.02g, heating in water bath to 45 ℃, light magnesium oxide (50g), Pulvis Talci (50g) and starch (20g) are added successively and stir, divide on the drip pan of shop, in being dried to water content below 60 ℃ below 3%, then the block of drying is broken into the granule below 14 orders, add magnesium stearate (7g) and Pulvis Talci (10g) mixing at last, cross 12 mesh sieve granulate, press 1000, packing, quality inspection.According to being grown up each 2 three times for each person every day.
Embodiment 4
Present embodiment is: get Folium Nelumbinis n-butanol extract 436.84g or Folium Nelumbinis ethyl acetate extract extractum 436.70g, divide on the drip pan of shop, put into 50 ℃ of baking ovens and be dried to water content below 3%, then the block of drying is broken into the powder below 8 orders, cross 8 mesh sieves, directly incapsulate according to 0.4g powder/grain, make 1000 capsules, packing.The Folium Nelumbinis n-butanol extract is taken three times for each person every day, each 5 capsules; The Folium Nelumbinis ethyl acetate extract is taken three times for each person every day, each 3 capsules.
It should be noted last that: above embodiment is only in order to explanation, and unrestricted technical scheme of the present invention, although the present invention is had been described in detail with reference to the foregoing description, those of ordinary skill in the art is to be understood that: still can make amendment or be equal to replacement the present invention, and not breaking away from any modification or partial replacement of the spirit and scope of the present invention, it all should be encompassed in the middle of the claim scope of the present invention.
Claims (8)
1. a Folium Nelumbinis extract is characterized in that, gets the Folium Nelumbinis dry product, through pulverizing, in the mixed solution of acetone and water, repeat merceration 2-4 time, sucking filtration, merging filtrate and reclaim under reduced pressure acetone, get the Folium Nelumbinis aqueous solution, use earlier ethyl acetate extraction for the first time, get ethyl acetate extract; To extract the back surplus solution and obtain n-butanol extract with n-butanol extraction.
2. Folium Nelumbinis extract according to claim 1 is characterized in that: the volume ratio of acetone and water is in the mixed solution of described acetone and water: acetone=(6-8)/(2-4).
3. Folium Nelumbinis extract according to claim 1 is characterized in that: described merceration divides 3 times, and 6-8 days for the first time, back twice 2-4 days.
4. the preparation method of a Folium Nelumbinis extract, it is characterized in that: may further comprise the steps: get the Folium Nelumbinis dry product, through pulverizing, in the mixed solution of acetone and water, repeat merceration 2-4 time, sucking filtration, merging filtrate and reclaim under reduced pressure acetone get the Folium Nelumbinis aqueous solution, use earlier ethyl acetate extraction for the first time, get ethyl acetate extract; To extract the back surplus solution and obtain n-butanol extract with n-butanol extraction.
5. the preparation method of Folium Nelumbinis extract according to claim 4, it is characterized in that: the volume ratio of acetone and water is in the mixed solution of described acetone and water: acetone=(6-8)/(2-4).
6. the preparation method of Folium Nelumbinis extract according to claim 4, it is characterized in that: described merceration divides 3 times, and 6-8 days for the first time, back twice each 2-4 days.
7. application that Folium Nelumbinis extract as claimed in claim 1 is used to prepare treatment hepatic disease medicine aspect.
8. application that Folium Nelumbinis extract as claimed in claim 1 is used to prepare the hepatic aspect.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100643537A CN101513451B (en) | 2009-03-10 | 2009-03-10 | Lotus Leaf extract, preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009100643537A CN101513451B (en) | 2009-03-10 | 2009-03-10 | Lotus Leaf extract, preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101513451A CN101513451A (en) | 2009-08-26 |
| CN101513451B true CN101513451B (en) | 2011-09-07 |
Family
ID=41038173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009100643537A Expired - Fee Related CN101513451B (en) | 2009-03-10 | 2009-03-10 | Lotus Leaf extract, preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101513451B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1152697C (en) * | 2000-09-28 | 2004-06-09 | 国家医药管理局上海医药工业研究院 | Oral cavity bacteriostatic composition containing extract of Chinese herb lotus leaf |
| CN1911116A (en) * | 2006-08-22 | 2007-02-14 | 沈松林 | Extractive of lotus leaf, prodn. method and application thereof |
| CN101007063A (en) * | 2006-09-09 | 2007-08-01 | 福州大学 | Preparation method of lotus leaf extract and use thereof |
-
2009
- 2009-03-10 CN CN2009100643537A patent/CN101513451B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1152697C (en) * | 2000-09-28 | 2004-06-09 | 国家医药管理局上海医药工业研究院 | Oral cavity bacteriostatic composition containing extract of Chinese herb lotus leaf |
| CN1911116A (en) * | 2006-08-22 | 2007-02-14 | 沈松林 | Extractive of lotus leaf, prodn. method and application thereof |
| CN101007063A (en) * | 2006-09-09 | 2007-08-01 | 福州大学 | Preparation method of lotus leaf extract and use thereof |
Non-Patent Citations (1)
| Title |
|---|
| 黄开颜，张志国.荷叶研究概况.《中国药业》.2008,第17卷(第11期),77-78. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101513451A (en) | 2009-08-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yu et al. | Subchronic toxicity studies of Radix Astragali extract in rats and dogs | |
| CN104825462A (en) | Anti-inflammation application of ganoderma leucocontextum extract | |
| CN102093459A (en) | Penthorum chinense pursh extract and preparation method and application thereof | |
| CN105395919A (en) | Composition containing black fungus extract and having effect of reducing blood fat and preparation method of composition | |
| CN103169788B (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN104523742B (en) | A kind of polysaccharide composition and its application with protect liver and raising immunization | |
| CN102356872B (en) | Blood lipid-lowering composite food | |
| CN107551001B (en) | A Chinese medicinal composition for preventing and treating alcoholic hepatic injury and its preparation method | |
| CN101433595A (en) | Desertliving cistanche alcohol extract as well as preparation method and use thereof | |
| CN103230435A (en) | Traditional Chinese medicine for prompting hepatocyte regeneration and preparation method of medicine | |
| CN100464755C (en) | Traditional Chinese medicine preparation with functions of immunological regulation for anti-chemical damage | |
| CN101390970B (en) | Traditional Chinese medicine for treating hepatitis B and preparation method thereof | |
| Garg et al. | Pharmacology of polygala tenuifolia and its significance in traditional Chinese medicine | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN101721455B (en) | Manyflower tickclove herb extract, and preparation method and application thereof | |
| CN101513451B (en) | Lotus Leaf extract, preparation method and application thereof | |
| CN101780239A (en) | Four-herb anti-tumor and anti-AIDS soft capsules and preparation process thereof | |
| CN103880913B (en) | A kind of compound and application thereof with hepatoprotective effect | |
| CN102940621B (en) | Application of methyl ferulic acid in preparation of medicine for preventing and curing hepatic fibrosis | |
| CN101816708B (en) | Chinese medicinal composition for curing rheumatism and preparation method thereof | |
| CN104367612A (en) | Application of alysicarpus vaginalis extract | |
| CN103864883B (en) | There is the triterpene saponin compound of liver protection function | |
| CN1795901B (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
| CN106822229A (en) | A kind of application of subprostrate sophora polysaccharide active component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Kang Wenyi Inventor after: Zhou Dapeng Inventor after: Zhang Wei Inventor after: Zhang Dongdi Inventor after: Guo Shuguang Inventor before: Kang Wenyi Inventor before: Guo Shuguang |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KANG WENYI GUO SHUGUANG TO: KANG WENYI ZHOU DAPENG ZHANG WEI ZHANG DONGDI GUO SHUGUANG |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110907 Termination date: 20150310 |
|
| EXPY | Termination of patent right or utility model |